stockrow
Monday 9 November 2026
Export RMTI’s income statement to Excel — free account
Rockwell Medical, Inc.
RMTIHealthcare Drug Manufacturers Specialty & Generic
Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +32.0%
- Free cash flow
- −12.9%
- Total debt
- −1.73%
Quarter to June 2026, against a year earlier
7.73
0.13
+1.71%
Follow RMTI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.57 | 0.43 | 0.52 | 0.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.08) | 13.10 | (210.78) | 10.49 | |
P/B ratio |
1.17 | 0.81 | 0.98 | 0.62 | |
Price to Tangible BV |
1.64 | 1.14 | 1.38 | 0.88 | |
EV/Sales |
0.45 | 0.29 | 0.30 | 0.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.46) | (29.99) | 7.67 | 2.11 | |
EV/FCF |
(6.09) | (5.07) | (26.75) | (6.24) | |
Quick Ratio |
3.34 | 3.46 | 3.32 | 2.96 | |
Current Ratio |
3.92 | 3.98 | 3.74 | 3.25 | |
Net Debt/EBITDA |
15.30 | (66.95) | 16.78 | 32.77 | |
Debt/Assets |
15.93% | 15.98% | 15.85% | 16.10% | |
Debt/Equity |
0.25 | 0.25 | 0.25 | 0.26 | |
Asset Turnover |
1.32 | 1.19 | 1.22 | 1.27 | |
Operating CF/Net income |
0.75 | (5.71) | 0.10 | (1.57) | |
Capex/Depreciation |
(0.36) | (0.14) | (0.42) | (1.06) | |
Interest Coverage |
(5.56) | (1.39) | (5.25) | (3.78) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.22% | |
Selling, General and Administrative Expense of Revenue |
24.21% | 23.31% | 25.25% | 23.98% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.18 | 0.18 | |
Share Based Compensation of Revenue |
3.34% | 2.49% | 2.76% | 2.27% | |
Graham Net Nets |
0.39 | 0.60 | 0.44 | 0.68 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.33%) | (17.99%) | (16.80%) | (24.32%) | |
Free Cash Flow Yield |
(13.03%) | (12.99%) | (2.17%) | (4.49%) | |
Revenue per Share |
4.42 | 5.10 | 4.40 | 4.49 | |
Operating CF per Share |
(0.36) | 0.64 | (0.04) | 0.53 | |
Capex per Share |
(0.06) | (0.02) | (0.06) | (0.16) | |
Free Cash Flow per Share |
(0.43) | 0.61 | (0.11) | 0.37 | |
Cash per Share |
6.58 | 6.95 | 6.06 | 6.26 | |
Shareholders Equity per Share |
10.28 | 10.28 | 9.10 | 8.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.28 | 10.28 | 9.10 | 8.86 | |
Free Cash Flow |
(1.54) | 2.21 | (0.42) | 1.46 | |
Working Capital |
27.93 | 28.58 | 27.08 | 25.19 | |
Capital Expenditures |
(0.23) | (0.09) | (0.25) | (0.62) | |
Net Current Asset Value |
17.05 | 18.00 | 15.38 | 14.92 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.61 | 8.22 | 9.25 | 8.19 | |
Average Payables |
2.07 | 2.43 | 2.69 | 2.34 | |
Average Inventory |
4.93 | 4.60 | 4.05 | 3.49 | |
Average Assets |
57.29 | 58.18 | 55.69 | 54.58 | |
Average Common Equity |
33.08 | 34.78 | 33.69 | 32.75 |
Columns are period end dates · fundamentals updated 26 Oct 2026